Inhibitors | Comment | Organism | Structure |
---|---|---|---|
11-[3-hydroxy-17-beta-hydroxyestr-5(10)-en-17alpha-yl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl]-undecanoic acid butyl-methyl-amide | selective inhibition of type 2 17beta-HSD | Homo sapiens | |
13-cis-retinoic acid | - |
Rattus norvegicus | |
17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone | IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM | Homo sapiens | |
17alpha-ethynyl-estradiol | 0.01 mM, 54% inhibition, reaction with 0.002 mM estradiol; inhibits oxidation of testosterone | Homo sapiens | |
17beta-dihydroequilin | 0.01 mM, 88% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
2-hydroxy-estradiol | 0.01 mM, 67% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
20alpha-dihydroprogesterone | 0.01 mM, 71% inhibition, reaction with 0.002 mM estradiol, inhibits oxidation of testosterone | Homo sapiens | |
3,4-dihydrobenzoic acid | 0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione | Homo sapiens | |
3-hydroxy-1,3,5(10)-estratriene-17beta-O,17alpha-butanolactone | selective for type 2 17beta-HSD versus types 1, 3, and 7 but not versus type 5 17beta-HSD | Homo sapiens | |
3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone | IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM | Homo sapiens | |
3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone | IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM | Homo sapiens | |
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone | IC50 for reduction of androst-4-en-3,17-dione: 0.0011 mM; IC50 for reduction of androst-4-en-3,17-dione: 0.0014 mM | Homo sapiens | |
3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone | IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase | Homo sapiens | |
5alpha-androstane-3alpha,17beta-diol | 0.01 mM, 87% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
5alpha-dihydrotestosterone | inhibits oxidation of testosterone | Homo sapiens | |
5beta-androstane-3alpha,17beta-diol | 0.01 mM, 83% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
5beta-dihydrotestosterone | inhibits oxidation of testosterone | Homo sapiens | |
9-cis-retinoic acid | weak | Homo sapiens | |
9-cis-retinoic acid | - |
Rattus norvegicus | |
danazol | inhibits oxidation of testosterone, 0.01 mM, 83% inhibition | Homo sapiens | |
estradiol | inhibits oxidation of testosterone | Homo sapiens | |
gallic acid | 0.001 mM, 50% inhibition, reduction of androst-4-en-3,17-dione | Homo sapiens | |
oleuropein glycoside | 0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione | Homo sapiens | |
spiro-gamma-lactone-estradiol | inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM | Homo sapiens | |
spironolactone | IC50 for oxidation of testosterone: 0.0011 mM | Homo sapiens | |
testosterone | 0.01 mM, 70% inhibition, reaction with 0.002 mM estradiol | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
microsome | - |
Homo sapiens | - |
- |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Rattus norvegicus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
A-431 cell | derived from an epidermoid carcinoma of the vulva | Homo sapiens | - |
HEK-293 cell | - |
Homo sapiens | - |
liver | - |
Homo sapiens | - |
liver | - |
Rattus norvegicus | - |
placenta | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
estradiol + NAD(P)+ | - |
Homo sapiens | estrone + NAD(P)H | - |
? | |
estradiol + NAD(P)+ | - |
Rattus norvegicus | estrone + NAD(P)H | - |
? | |
testosterone + NAD(P)+ | - |
Homo sapiens | androst-4-en-3,17-dione + NAD(P)H + H+ | - |
r | |
testosterone + NAD(P)+ | - |
Rattus norvegicus | androst-4-en-3,17-dione + NAD(P)H + H+ | - |
r |
Synonyms | Comment | Organism |
---|---|---|
type 2 17beta-HSD | - |
Homo sapiens |
type 2 17beta-HSD | - |
Rattus norvegicus |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
NAD+ | - |
Homo sapiens | |
NAD+ | - |
Rattus norvegicus | |
NADH | - |
Homo sapiens | |
NADH | - |
Rattus norvegicus | |
NADP+ | - |
Homo sapiens | |
NADP+ | - |
Rattus norvegicus | |
NADPH | - |
Homo sapiens | |
NADPH | - |
Rattus norvegicus |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.0003 | - |
17alpha-ethynyl-estradiol | - |
Homo sapiens | |
0.0006 | - |
danazol | - |
Homo sapiens | |
0.0008 | - |
estradiol | - |
Homo sapiens | |
0.0024 | - |
13-cis-retinoic acid | - |
Rattus norvegicus | |
0.0041 | - |
9-cis-retinoic acid | - |
Rattus norvegicus |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.00025 | - |
inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM | Homo sapiens | spiro-gamma-lactone-estradiol | |
0.0007 | - |
IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone | |
0.0009 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM | Homo sapiens | 17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone | |
0.001 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone | |
0.001 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone | |
0.0011 | - |
IC50 for oxidation of testosterone: 0.0011 mM | Homo sapiens | spironolactone | |
0.0011 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.0011 mM | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone | |
0.0014 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.0014 mM | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone |